Cellectar Biosciences
CLRB
19 hedge funds and large institutions have $3.85M invested in Cellectar Biosciences in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 4 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
25% more capital invested
Capital invested by funds: $3.08M → $3.85M (+$772K)
0.05% less ownership
Funds ownership: 0.55% → 0.5% (-0.05%)
5% less funds holding
Funds holding: 20 → 19 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$238K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$31.4K |
| 3 |
CB
Commerce Bank
Kansas City,
Missouri
|
+$23.6K |
| 4 |
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
|
+$23.6K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.72K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$266K |
| 2 |
Renaissance Technologies
New York
|
-$83K |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$67.5K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$60K |
| 5 |
MS
Maven Securities
St Helier,
Jersey
|
-$48.8K |
CLRB Hedge Fund Activity: Q3 2023 in Review
19 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q3 2023, worth a combined $3.85M — up 25% from $3.08M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of CLRB and 3 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 5 added.
The largest buyer was Acuta Capital Partners, opening a new position worth an estimated $238K. The largest seller was AIGH Capital Management, cutting an estimated $266K.
- 19 institutional investors held Cellectar Biosciences (CLRB) as of Q3 2023, down from 20 in Q2 2023.
- Funds reported $3.85M of Cellectar Biosciences stock for Q3 2023, up 25% quarter-over-quarter.
- 3 funds opened new Cellectar Biosciences positions in Q3 2023 and 4 closed out, a net change of -1 holder.
- The largest Cellectar Biosciences buyer in Q3 2023 was Acuta Capital Partners, an estimated $238K added.
- The largest Cellectar Biosciences seller in Q3 2023 was AIGH Capital Management, an estimated $266K sold.
Based on aggregated 13F filings for Q3 2023.